Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROY (APGOT-OV14)
2026-527010-23-00Phase 2Authorised
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan and bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression-free survival in HER2 IHC 1+/2+/3+ population. Planned start Sep 2026; status: authorised.
02
Drugs
trastuzumab deruxtecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2026-527010-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527010-23-00.